140 related articles for article (PubMed ID: 9129144)
21. Novel germline mutation of the p53 tumor suppressor gene in a child with incidentally discovered adrenal cortical carcinoma.
Grayson GH; Moore S; Schneider BG; Saldivar V; Hensel CH
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):341-7. PubMed ID: 7978053
[TBL] [Abstract][Full Text] [Related]
22. Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.
Felix CA; Nau MM; Takahashi T; Mitsudomi T; Chiba I; Poplack DG; Reaman GH; Cole DE; Letterio JJ; Whang-Peng J
J Clin Invest; 1992 Feb; 89(2):640-7. PubMed ID: 1737852
[TBL] [Abstract][Full Text] [Related]
23. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
24. [Correlation between p53 gene mutation and protein expression in 30 cases of human lung cancer].
Zhang J; Zheng J; Fang W
Zhonghua Yi Xue Za Zhi; 1998 Nov; 78(11):846-9. PubMed ID: 11038779
[TBL] [Abstract][Full Text] [Related]
25. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
Kouidou S; Malousi A; Maglaveras N
Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
[TBL] [Abstract][Full Text] [Related]
26. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
27. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
Pötzsch C; Voigtländer T; Lübbert M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
[TBL] [Abstract][Full Text] [Related]
28. Characterization of germline TP53 splicing mutations and their genetic and functional analysis.
Varley JM; Attwooll C; White G; McGown G; Thorncroft M; Kelsey AM; Greaves M; Boyle J; Birch JM
Oncogene; 2001 May; 20(21):2647-54. PubMed ID: 11420676
[TBL] [Abstract][Full Text] [Related]
29. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
30. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
Wu CC; Shete S; Amos CI; Strong LC
Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
[TBL] [Abstract][Full Text] [Related]
31. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family.
Lomax ME; Barnes DM; Gilchrist R; Picksley SM; Varley JM; Camplejohn RS
Oncogene; 1997 Apr; 14(15):1869-74. PubMed ID: 9150393
[TBL] [Abstract][Full Text] [Related]
32. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
34. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
[TBL] [Abstract][Full Text] [Related]
35. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
36. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
37. Different patterns of p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of microdissected specimens.
Yasunaga Y; Shin M; Fujita MQ; Nonomura N; Miki T; Okuyama A; Aozasa K
Lab Invest; 1998 Oct; 78(10):1275-9. PubMed ID: 9800953
[TBL] [Abstract][Full Text] [Related]
38. A novel germ-line mutation in the noncoding region of the p53 gene in a Li-Fraumeni family.
Barel D; Avigad S; Mor C; Fogel M; Cohen IJ; Zaizov R
Cancer Genet Cytogenet; 1998 May; 103(1):1-6. PubMed ID: 9595036
[TBL] [Abstract][Full Text] [Related]
39. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
40. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]